Steven Goldberg, MD
Cardiovascular Disease · Great Neck, NYNPI 1205839255
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,223 of the $77,991 with a category attached, or 81.1%. 29 manufacturers reported payments, led by Boehringer Ingelheim at 44.7% of the total. Reporting peaked in 2021 at $24,240 and has fallen 96.3% since, to $902 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $244.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$35K
- Esperion Therapeutics, Inc.$19K
- AstraZeneca$10K
- Lilly USA, LLC$6K
- Abbott$926
- Boston Scientific$895
- plus $6K from 23 others
Across 1 payment — averaging $12,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$12K
What the payments were for
- Consulting fees$4,0085%
- Speaking & faculty fees$63,22381%
- Travel & lodging$1540%
- Food & beverage$10,56414%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 38 | $34,849 |
| Esperion Therapeutics, Inc. | 23 | $19,481 |
| AstraZeneca | 19 | $10,379 |
| Lilly USA, LLC | 11 | $5,948 |
| Abbott | 13 | $926 |
| Boston Scientific | 14 | $895 |
| E.r. Squibb & Sons, L.L.C. | 23 | $763 |
| Johnson & Johnson | 39 | $691 |
| Novartis | 36 | $562 |
| Pfizer | 27 | $480 |
| Medtronic | 4 | $441 |
| Heartflow, Inc. | 4 | $427 |
| Novo Nordisk | 22 | $333 |
| Edwards Lifesciences | 2 | $319 |
| Amgen | 13 | $281 |
| Cvrx, Inc. | 2 | $243 |
| Biohaven Pharmaceuticals, Inc. | 2 | $213 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| AbbVie | 8 | $120 |
| GSK | 1 | $116 |
| Merck | 4 | $111 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| Althera Pharmaceuticals LLC | 3 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Bardy Diagnostics, Inc. | 1 | $39 |
| Terumo Medical Corporation | 1 | $38 |
| Coala Life Inc | 1 | $24 |
| Lundbeck LLC | 1 | $13 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$40,048
- NEXLIZET$19,362
- NEXLETOL$19,362
- FARXIGA$8,028
- LOKELMA$1,860
- PRADAXA$520
- CAMZYOS$358
- FFRct$344
- COBALT DR MRI SURESCAN$299
- CARDIOMEMS$281
- FreeStyle Libre Pro$250
- XARELTO$250
- Watchman$228
- WATCHMAN Access System$226
- SAPIEN 3 Ultra RESILIA$223
- Barostim Neo System$176
- NAVITOR$142
- WATCHMAN FLX$138
- Reveal LINQ$126
- VYNDAQEL$126
How this compares
$77,991 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $135,140 |
| OzempicSemaglutide | 118 | $112,507 |
| MounjaroTirzepatide | 74 | $99,230 |
| XareltoRivaroxaban | 70 | $90,843 |
| JardianceEmpagliflozin | 58 | $76,780 |
| RybelsusSemaglutide | 43 | $51,987 |
| EntrestoSacubitril/Valsartan | 44 | $49,055 |
| FarxigaDapagliflozin Propanediol | 46 | $48,246 |
| Repatha SureclickEvolocumab | 52 | $35,205 |
| JanuviaSitagliptin Phosphate | 22 | $28,661 |
| NexlizetBempedoic Acid/Ezetimibe | 19 | $18,440 |
| NexletolBempedoic Acid | 32 | $17,285 |
| Metoprolol Succinate | 525 | $9,146 |
| Ezetimibe | 235 | $7,434 |
| Sildenafil Citrate | 17 | $5,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $333 | $164,494161 claims |
| PfizerEliquis | $480 | $135,140159 claims |
| Lilly USA, LLCMounjaro | $5,948 | $99,23074 claims |
| Johnson & JohnsonXarelto | $691 | $90,84370 claims |
| Boehringer IngelheimJardiance | $34,849 | $76,78058 claims |
| NovartisEntresto | $562 | $49,05544 claims |
| AstraZenecaFarxiga | $10,379 | $48,24646 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $19,481 | $35,72551 claims |
| MerckJanuvia | $111 | $28,66122 claims |
| AbbVieSynthroid | $120 | $2,84636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Great Neck
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.